<DOC>
	<DOCNO>NCT01419041</DOCNO>
	<brief_summary>The present study conduct evaluate whether severe renal impairment effect crizotinib Pharmacokinetics .</brief_summary>
	<brief_title>A Study Evaluate The Pharmacokinetics Of Crizotinib ( PF-02341066 ) In Subjects With Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>All Subjects Healthy male and/or female non childbearing potential subject age 18 65 year , inclusive ( 'healthy ' define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG , clinical laboratory test ) . Body Mass Index ( BMI ) 18 40 kg/m2 inclusive ; total body weight &gt; 50 kg ( &gt; 110 lb ) . Subjects Normal Renal Function ( Group 1 ) Normal renal function ( CLcr = &gt; 90 mL/min ) screening period . Matched 1to1 subject Group 2 respect age ( +/5 year ) , weight ( +/10 kg ) , gender , race accord protocol . Subjects Severe Renal Impairment ( Groups 2 ) Good general health commensurate population chronic kidney disease . Severe renal impairment ( CLcr &lt; 30 mL/min ) screening period . All Subjects Renal allograft recipient . Any condition possibly affect drug absorption . 12 lead ECG demonstrate QTc &gt; 470 msec screening . Urinary incontinence without catheterization . A positive urine drug screen . History regular alcohol consumption . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 half life precede first dose study medication . Pregnant nursing female ; female childbearing potential , include tubal ligation . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . Subjects Severe Renal Impairment ( Groups 2 ) Subjects significant hepatic , cardiac pulmonary disease ( apart stable ischemic heart disease ) , subject clinically nephrotic . Subjects require hemodialysis . Subjects strict fluid restriction ( ie , &lt; 1500 mL/24 hour ) . Significant bleeding diathesis could preclude multiple venipuncture . Use food drug CYP3A4 inhibitor inducer . Herbal supplement hormone replacement therapy must discontinue 28 day prior first dose trial medication Concurrent use drug CYP3A4 substrates narrow therapeutic index .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>renal impairment</keyword>
	<keyword>crizotinib</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>